Evidence map›Paper›PMID 40046502›Full record

ArticleFrontiers in artificial intelligence2025

XAI-MRI: an ensemble dual-modality approach for 3D brain tumor segmentation using magnetic resonance imaging.

Ahmeed Suliman Farhan, Muhammad Khalid, Umar Manzoor

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmeed Suliman FarhanSchool of Computer Sciences, University of Hull, Hull, United Kingdom.
Muhammad KhalidComputer Center, University of Anbar, Ramadi, Iraq.
Umar ManzoorSchool of Computer Science, University of Wolverhampton, Wolverhampton, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain tumor segmentation from Magnetic Resonance Images (MRI) presents significant challenges due to the complex nature of brain tumor tissues. This complexity poses a significant challenge in distinguishing tumor tissues from healthy tissues, particularly when radiologists rely on manual segmentation. Reliable and accurate segmentation is crucial for effective tumor grading and treatment planning. In this paper, we proposed a novel ensemble dual-modality approach for 3D brain tumor segmentation using MRI. Initially, individual U-Net models are trained and evaluated on single MRI modalities (T1, T2, T1ce, and FLAIR) to establish each modality's performance. Subsequently, we trained U-net models using combinations of the best-performing modalities to exploit the complementary information and improve segmentation accuracy. Finally, we introduced the ensemble dual-modality by combining the two best-performing pre-trained dual-modalities models to enhance segmentation performance. Experimental results show that the proposed model enhanced the segmentation result and achieved a Dice Coefficient of 97.73% and a Mean IoU of 60.08%. The results illustrate that the ensemble dual-modality approach outperforms single-modality and dual-modality models. Grad-CAM visualizations are implemented, generating heat maps that highlight tumor regions and provide useful information to clinicians about how the model made the decision, increasing their confidence in using deep learning-based systems. Our code publicly available at: https://github.com/Ahmeed-Suliman-Farhan/Ensemble-Dual-Modality-Approach.

Indexed as

brain tumor segmentationconvolutional neural networkdeep learningensemble dual-modalityGrad-CAMMRI imagesU-netXAI

Identifiers

PMID40046502
PMCPMC11880613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.